Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive T-cell malignancy that arises in
a proportion of individuals who are long-term carriers of human T-lymphotropic virus type 1 …

Simple Summary CCR4 is a chemokine receptor selectively expressed on normal T cell
subsets such as type 2 helper T cells, skin-homing T cells and regulatory T cells, and on skin …

Human T-lymphotropic virus type 1 (HTLV-1) infection may cause serious disease, while
pathogenicity of HTLV-2 is less certain. There are no screening or surveillance programs for …

Natural selection signatures across Japanese subpopulations are under-explored. Here we
conducted genome-wide selection scans with 622,926 single nucleotide polymorphisms for …

Human T-cell leukemia virus type I (HTLV-1) causes adult T-cell leukemia/lymphoma (ATL)
in 5% of infected people with a decades-long latency. Charles RM Bangham reviews the …

HTLV-1 uveitis (HU) is the third clinical entity to be designated as an HTLV-1-associated
disease. Although HU is considered to be the second-most frequent HTLV-1-associated …

Background Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia-
lymphoma (ATL) and HTLV-1-associated myelopathy-tropical spastic paraparesis …

Adult T-cell leukemia/lymphoma (ATLL) originates from human T-cell leukemia virus type 1
(HTLV-1) infection due to the activation of the nuclear factor-κB (NF-κB) signaling pathway to …

An estimated 1.08 million carriers of human T‐lymphotropic virus 1 (HTLV‐1) were living in
Japan in 2006–2007. Since that study, new data on horizontal infection, nationwide …

Mogamulizumab is a first‐in‐class IgG1k monoclonal antibody that selectively targets the
chemokine receptor type 4. The drug has received Food and Drug administration …